Search

Your search keyword '"van Rijn, Roos S."' showing total 21 results
Start Over Author "van Rijn, Roos S."
21 results on '"van Rijn, Roos S."'

1. Adjuvant treatment for melanoma in clinical practice – Trial versus reality

Author

de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., and Wouters, Michel W.J.M.

Published
2021
Full Text
View/download PDF

2. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Published
2021
Full Text
View/download PDF

3. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Published
2022
Full Text
View/download PDF

4. Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases

Author

Ismail, Rawa K., Sikkes, Nienke O., Wouters, Michel W.J.M., Hilarius, Doranne L., Pasmooij, Anna M.G., van den Eertwegh, Alfonsus J.M., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B.A.G., Hospers, Geke A.P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P.M., ten Tije, Bert-Jan, van der Veldt, Astrid A.M., Vreugdenhil, Art, van Dartel, Maaike, and de Boer, Anthonius

Published
2021
Full Text
View/download PDF

5. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., ten Tije, Bert-Jan J., van der Veldt, Astrid A. M., Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Published
2021
Full Text
View/download PDF

6. ALL-tRNAseq enables robust tRNA profiling in tissue samples

Author

Scheepbouwer, Chantal, primary, Aparicio-Puerta, Ernesto, additional, Gomez-Martin, Cristina, additional, Verschueren, Heleen, additional, van Eijndhoven, Monique, additional, Wedekind, Laurine E., additional, Giannoukakos, Stavros, additional, Hijmering, Nathalie, additional, Gasparotto, Lisa, additional, van der Galien, Hilde T., additional, van Rijn, Roos S., additional, Aronica, Eleonora, additional, Kibbelaar, Robby, additional, Heine, Vivi M., additional, Wesseling, Pieter, additional, Noske, David P., additional, Vandertop, W. Peter, additional, de Jong, Daphne, additional, Pegtel, D. Michiel, additional, Hackenberg, Michael, additional, Wurdinger, Tom, additional, Gerber, Alan, additional, and Koppers-Lalic, Danijela, additional

Published
2023
Full Text
View/download PDF

7. Correction:First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J. M., Internal medicine, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), Medical oncology, AII - Cancer immunology, CCA - Cancer biology and immunology, and CCA - Cancer Treatment and quality of life

Abstract

The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.

Published
2022
Full Text
View/download PDF

8. Response to immune checkpoint inhibitors in acral melanoma:A nationwide cohort study

Author

van Not, Olivier J, de Meza, Melissa M, van den Eertwegh, Alfons J M, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, van Breeschoten, Jesper, de Groot, Jan-Willem B, Hospers, Geke A P, Ismail, Rawa K, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Stevense-den Boer, Marion A M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Bonenkamp, Han J, Boers-Sonderen, Marye J, Blokx, Willeke A M, Wouters, Michel W J M, Suijkerbuijk, Karijn P M, van Not, Olivier J, de Meza, Melissa M, van den Eertwegh, Alfons J M, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, van Breeschoten, Jesper, de Groot, Jan-Willem B, Hospers, Geke A P, Ismail, Rawa K, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Stevense-den Boer, Marion A M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Bonenkamp, Han J, Boers-Sonderen, Marye J, Blokx, Willeke A M, Wouters, Michel W J M, and Suijkerbuijk, Karijn P M

Abstract

Background: Recent reports suggest the limited efficacy of immune checkpoints inhibitors in advanced acral melanoma (AM). This study aims to investigate the clinical outcomes of immune checkpoint inhibitors in patients with stage III and IV AM and compare them to cutaneous melanoma (CM). Methods: We included patients with advanced AM and CM treated with first-line anti-programmed cell death (PD)-1 monotherapy or ipilimumab-nivolumab registered in the prospective nationwide Dutch Melanoma Treatment Registry. Objective response rates, progression-free survival (PFS) and overall survival (OS) were calculated. A Cox proportional hazard model was used to assess the prognostic factors with PFS and OS. Results: In total, 2058 patients (88 AM and 1970 CM) with advanced melanoma were included. First-line objective response rates were 34% for AM versus 54% for CM in the advanced anti-PD-1 cohort and 33% for AM versus 53% for CM in the advanced ipilimumab-nivolumab cohort. The Median PFS was significantly shorter for anti-PD-1 treated AM patients (3.1 months; 95%CI: 2.8–5.6) than patients with CM (10.1 months; 95%CI: 8.5–12.2) (P < 0.001). In patients with advanced melanoma, AM was significantly associated with a higher risk of progression (HRadj 1.63; 95%CI: 1.26–2.11; P < 0.001) and death (HRadj 1.54; 95%CI: 1.15–2.06; P = 0.004) than CM. Conclusions: This study shows lower effectiveness of anti-PD -1 monotherapy and ipilimumab-nivolumab in AM, with lower response rates, PFS and OS than CM. This group of patients should be prioritised in the development of alternative treatment strategies.

Published
2022

9. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Pathologie Pathologen staf, van Breeschoten, Jesper, Wouters, Michel W J M, Hilarius, Doranne L, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Tije, Bert-Jan J Ten, Veldt, Astrid A M van der, Vreugdenhil, Art, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, MS Medische Oncologie, Infection & Immunity, Cancer, Pathologie Pathologen staf, van Breeschoten, Jesper, Wouters, Michel W J M, Hilarius, Doranne L, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Tije, Bert-Jan J Ten, Veldt, Astrid A M van der, Vreugdenhil, Art, Boers-Sonderen, Marye J, and van den Eertwegh, Alfonsus J M

Published
2022

10. Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study

Author

Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, van Not, Olivier J, de Meza, Melissa M, van den Eertwegh, Alfons J M, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, van Breeschoten, Jesper, de Groot, Jan-Willem B, Hospers, Geke A P, Ismail, Rawa K, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Stevense-den Boer, Marion A M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Bonenkamp, Han J, Boers-Sonderen, Marye J, Blokx, Willeke A M, Wouters, Michel W J M, Suijkerbuijk, Karijn P M, Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, van Not, Olivier J, de Meza, Melissa M, van den Eertwegh, Alfons J M, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, van Breeschoten, Jesper, de Groot, Jan-Willem B, Hospers, Geke A P, Ismail, Rawa K, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Stevense-den Boer, Marion A M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Bonenkamp, Han J, Boers-Sonderen, Marye J, Blokx, Willeke A M, Wouters, Michel W J M, and Suijkerbuijk, Karijn P M

Published
2022

11. Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study

Author

van Not, Olivier J., primary, de Meza, Melissa M., additional, van den Eertwegh, Alfons J.M., additional, Haanen, John B., additional, Blank, Christian U., additional, Aarts, Maureen J.B., additional, van den Berkmortel, Franchette W.P.J., additional, van Breeschoten, Jesper, additional, de Groot, Jan-Willem B., additional, Hospers, Geke A.P., additional, Ismail, Rawa K., additional, Kapiteijn, Ellen, additional, Piersma, Djura, additional, van Rijn, Roos S., additional, Stevense-den Boer, Marion A.M., additional, van der Veldt, Astrid A.M., additional, Vreugdenhil, Gerard, additional, Bonenkamp, Han J., additional, Boers-Sonderen, Marye J., additional, Blokx, Willeke A.M., additional, Wouters, Michel W.J.M., additional, and Suijkerbuijk, Karijn P.M., additional

Published
2022
Full Text
View/download PDF

12. Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases

Author

Ismail, Rawa K, Sikkes, Nienke O, Wouters, Michel W J M, Hilarius, Doranne L, Pasmooij, Anna M G, van den Eertwegh, Alfonsus J M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Ten Tije, Bert-Jan, van der Veldt, Astrid A M, Vreugdenhil, Art, van Dartel, Maaike, de Boer, Anthonius, Ismail, Rawa K, Sikkes, Nienke O, Wouters, Michel W J M, Hilarius, Doranne L, Pasmooij, Anna M G, van den Eertwegh, Alfonsus J M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Ten Tije, Bert-Jan, van der Veldt, Astrid A M, Vreugdenhil, Art, van Dartel, Maaike, and de Boer, Anthonius

Abstract

Postapproval trials and patient registries have their pros and cons in the generation of postapproval data. No direct comparison between clinical outcomes of these data sources currently exists for advanced melanoma patients. We aimed to investigate whether a patient registry can complement or even replace postapproval trials. Postapproval single-arm clinical trial data from the Medicines Evaluation Board and real-world data from the Dutch Melanoma Treatment Registry were used. The study population consisted of advanced melanoma patients with brain metastases treated with targeted therapies (BRAF- or BRAF-MEK inhibitors) in the first line. A Cox hazard regression model and a propensity score matching (PSM) model were used to compare the two patient populations. Compared to patients treated in postapproval trials (n = 467), real-world patients (n = 602) had significantly higher age, higher ECOG performance status, more often ≥3 organ involvement and more symptomatic brain metastases. Lactate dehydrogenase levels were similar between both groups. The unadjusted median overall survival (mOS) in postapproval clinical trial patients was 8.7 (95% CI, 8.1-10.4) months compared to 7.2 (95% CI, 6.5-7.7) months (P < 0.01) in real-world patients. With the Cox hazard regression model, survival was adjusted for prognostic factors, which led to a statistically insignificant difference in mOS for trial and real-world patients of 8.7 (95% CI, 7.9-10.4) months compared to 7.3 (95% CI, 6.3-7.9) months, respectively. The PSM model resulted in 310 matched patients with similar survival (P = 0.9). Clinical outcomes of both data sources were similar. Registries could be a complementary data source to postapproval clinical trials to establish information on clinical outcomes in specific subpopulations.

Published
2021

13. Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Ismail, Rawa K, Sikkes, Nienke O, Wouters, Michel W J M, Hilarius, Doranne L, Pasmooij, Anna M G, van den Eertwegh, Alfonsus J M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Ten Tije, Bert-Jan, van der Veldt, Astrid A M, Vreugdenhil, Art, van Dartel, Maaike, de Boer, Anthonius, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Ismail, Rawa K, Sikkes, Nienke O, Wouters, Michel W J M, Hilarius, Doranne L, Pasmooij, Anna M G, van den Eertwegh, Alfonsus J M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Ten Tije, Bert-Jan, van der Veldt, Astrid A M, Vreugdenhil, Art, van Dartel, Maaike, and de Boer, Anthonius

Published
2021

14. Adjuvant treatment for melanoma in clinical practice – Trial versus reality

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., Wouters, Michel W.J.M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., and Wouters, Michel W.J.M.

Published
2021

15. Adjuvant treatment for melanoma in clinical practice – Trial versus reality

Author

Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., Wouters, Michel W.J.M., Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., and Wouters, Michel W.J.M.

Published
2021

16. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Pathologie Pathologen staf, van Breeschoten, Jesper, Wouters, Michel W J M, Hilarius, Doranne L, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Ten Tije, Bert-Jan J, van der Veldt, Astrid A M, Vreugdenhil, Art, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, MS Medische Oncologie, Infection & Immunity, Cancer, Pathologie Pathologen staf, van Breeschoten, Jesper, Wouters, Michel W J M, Hilarius, Doranne L, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Ten Tije, Bert-Jan J, van der Veldt, Astrid A M, Vreugdenhil, Art, Boers-Sonderen, Marye J, and van den Eertwegh, Alfonsus J M

Published
2021

17. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Pathologie Pathologen staf, van Breeschoten, Jesper, Wouters, Michel W J M, Hilarius, Doranne L, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Tije, Bert-Jan J Ten, Veldt, Astrid A M van der, Vreugdenhil, Art, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, MS Medische Oncologie, Infection & Immunity, Cancer, Pathologie Pathologen staf, van Breeschoten, Jesper, Wouters, Michel W J M, Hilarius, Doranne L, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Tije, Bert-Jan J Ten, Veldt, Astrid A M van der, Vreugdenhil, Art, Boers-Sonderen, Marye J, and van den Eertwegh, Alfonsus J M

Published
2021

19. Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases

Author

Ismail, Rawa K., primary, Sikkes, Nienke O., additional, Wouters, Michel W.J.M., additional, Hilarius, Doranne L., additional, Pasmooij, Anna M.G., additional, van den Eertwegh, Alfonsus J.M., additional, Aarts, Maureen J.B., additional, van den Berkmortel, Franchette W.P.J., additional, Boers-Sonderen, Marye J., additional, de Groot, Jan Willem B., additional, Haanen, John B.A.G., additional, Hospers, Geke A.P., additional, Kapiteijn, Ellen, additional, Piersma, Djura, additional, van Rijn, Roos S., additional, Suijkerbuijk, Karijn P.M., additional, ten Tije, Bert-Jan, additional, van der Veldt, Astrid A.M., additional, Vreugdenhil, Art, additional, van Dartel, Maaike, additional, and de Boer, Anthonius, additional

Published
2020
Full Text
View/download PDF

20. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Abstract

Background: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy in the treatment of BRAFV600-mutant advanced melanoma. Until now, data are inconclusive on which therapy to use as first-line treatment. The aim of this study was to use propensity score matching to compare first-line anti-PD-1 monotherapy vs. BRAF/MEK inhibitors in advanced BRAFV600-mutant melanoma patients.Methods: We selected patients diagnosed between 2014 and 2017 with advanced melanoma and a known BRAFV600-mutation treated with first-line BRAF/MEK inhibitors or anti-PD-1 antibodies, registered in the Dutch Melanoma Treatment Registry. Patients were matched based on their propensity scores using the nearest neighbour and the optimal matching method.Results: Between 2014 and 2017, a total of 330 and 254 advanced melanoma patients received BRAF/MEK inhibitors and anti-PD-1 monotherapy as first-line systemic therapy. In the matched cohort, patients receiving anti-PD-1 antibodies as a first-line treatment had a higher median and 2-year overall survival compared to patients treated with first-line BRAF/MEK inhibitors, 42.3 months (95% CI: 37.3-NE) vs. 19.8 months (95% CI: 16.7-24.3) and 65.4% (95% CI: 58.1-73.6) vs. 41.7% (95% CI: 34.2-51.0).Conclusions: Our data suggest that in the matched BRAFV600-mutant advanced melanoma patients, anti-PD-1 monotherapy is the preferred first-line treatment in patients with relatively favourable patient and tumour characteristics. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

21. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results